Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. - Wikidata - wikimedia - TriplyDB

Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.

Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.

http://www.wikidata.org/entity/Q34733171

about

Lutein, Zeaxanthin, and meso-Zeaxanthin in the Clinical Management of Eye Disease Fish Consumption and Age-Related Macular Degeneration Incidence: A Meta-Analysis and Systematic Review of Prospective Cohort Studies The relationship between BCMO1 gene variants and macular pigment optical density in persons with and without age-related macular degeneration.Macular pigment optical density measurements by one-wavelength reflection photometry--influence of cataract surgery on the measurement results.REPRODUCIBILITY OF MACULAR PIGMENT OPTICAL DENSITY MEASUREMENT BY TWO-WAVELENGTH AUTOFLUORESCENCE IN A CLINICAL SETTING.Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density.ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.Preliminary analysis of the relationship between serum lutein and zeaxanthin levels and macular pigment optical density.Lutein and Zeaxanthin-Food Sources, Bioavailability and Dietary Variety in Age-Related Macular Degeneration Protection.Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: A randomized clinical trial.Dietary modification and supplementation for the treatment of age-related macular degeneration.Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.Lutein and Zeaxanthin Isomers in Eye Health and Disease.The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration.Effect of Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 on Macular Pigment: A Randomized Clinical Trial.Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity.MACULAR PIGMENT DISTRIBUTION RESPONSES TO HIGH-DOSE ZEAXANTHIN SUPPLEMENTATION IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2.Berberine Protects Human Retinal Pigment Epithelial Cells from Hydrogen Peroxide-Induced Oxidative Damage through Activation of AMPK.Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial The Effect of Lutein on Eye and Extra-Eye Health

P2860

Q26773085-086F0F1D-EDE8-49E2-B349-351DF653C301 Q28066446-879B22B5-E63D-4ECA-AA7F-45EB672C4F2D Q35106624-18F2B7F0-F067-4386-B753-8735287956BE Q35154311-3F5E799C-06EA-41C9-8F7D-545BEC551576 Q35865877-0FF94681-8628-4876-BFF2-B4E48BB80156 Q36019914-1CE48AB1-E551-4A39-8F31-F2EF5167C38A Q36078526-1DA4F4DD-4BF7-4BA3-BCB6-79ED9EB042F6 Q36374238-E70D42E9-8B5E-4C13-9D2E-005B37A0007B Q37395594-4D027960-36B5-410B-BCAD-48947B8E2DE8 Q37673168-F4EE9396-E47D-47F6-8BD9-BC54548B0203 Q37716339-1082920E-582D-414A-AEB0-1C69E1B6F31C Q38529695-62E41076-C12F-4392-8497-1EA271C0577B Q38653249-0EF3608C-F26C-40C5-8410-EEDE766C80FD Q38901504-0C7E231D-BE32-4907-B0A4-6FA275EC10FE Q39092535-35AB42DF-D9F8-4CF9-ABB3-F14DCCCA7AF8 Q47253521-AC5846E2-50A1-4717-8C84-694393A1358D Q51746396-3ED43E6C-0FAE-4EB3-9FB2-CD78613B0404 Q52927684-8F3530D1-C789-4C1F-AD83-D1049642C03E Q55691409-ECD2F894-2817-4155-9D03-59E8F11F9827 Q57493306-89776529-DE4C-428D-A820-72B232BAC7F0 Q58722677-CA3EC29D-83DB-4D45-AC76-6922A062B88C

P2860

Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.

http://www.wikidata.org/entity/Q34733171

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@ast

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@en

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@nl

type

label

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@ast

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@en

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@nl

prefLabel

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@ast

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@en

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@nl

P1433

Q34733171-44AB0DD6-7FC0-49A7-B133-1934DD5732E4

P1476

Q34733171-94FFD867-3EF3-4305-838F-08664B9149BA

P2093

Q34733171-1183246B-E825-42A2-840C-5E03A951A5DB

Q34733171-4229B2F5-3083-49A2-A107-60A79FA07E19

Q34733171-5B70B52D-5B98-4F2A-86F6-8F6175169DA2

Q34733171-7C9B6EB5-18AB-4A19-8BB6-C532353683BE

Q34733171-BA44E3EE-EBE3-486E-833E-DE3856C9EF9E

Q34733171-FE920F58-5F28-439F-B317-EBCE1BB229C8

P2860

Q34733171-0384641E-D121-4A6C-8081-7DF92A1CE0FC

Q34733171-03E6328D-2B50-4B63-97AC-05A2C12C341C

Q34733171-05460F20-7C71-439F-8541-1CF8382D1D7D

Q34733171-07DAF2BD-AC87-407F-A66B-B38931A20846

Q34733171-0AD2C1D7-4B5F-4056-B3F3-3301A2F172BA

Q34733171-1DA684EF-31F8-420B-A462-15475B650C0C

Q34733171-2471A3FE-4569-43DD-9314-6B7702E7FFE9

Q34733171-29B6DA5F-7CFD-4D44-A411-188191EBB648

Q34733171-2CE66329-DE29-43EB-BBBC-81B2D75FF47A

Q34733171-324F5C79-CBD2-48AF-A6F2-952E48F027B0

P2888

Q34733171-899037C2-6138-40CB-96CF-B8176EBC88EA

P304

Q34733171-C5ED5929-1CA3-4086-86A0-8FFEE7EAAFDB

P31

Q34733171-2373A7E4-F89F-4065-A0E1-85CD0D2070B4

P356

Q34733171-DECF85B8-292E-4CE4-99A5-A37FEB936405

P433

Q34733171-1B295C81-6BBF-4D5C-B12B-1EBDC0E7CF0E

P478

Q34733171-9B83A700-DCCC-4710-9917-6F8E2C3220D4

P577

Q34733171-76E86237-8CBF-4626-9574-18BCF42FB709

P5875

Q34733171-D7B4425E-4DC5-426A-970D-B13E12E3DE8A

P6179

Q34733171-AF1EB476-B2F4-426F-9DB3-B07777E6276F

P698

Q34733171-C2DF5B32-08B0-4032-86DD-1D68DAD7E836

P356

S00417-013-2376-6

P1433

Graefe's Archive for Clinical and Experimental Ophthalmology

P1476

Long term effects of lutein, z ...... MD patients: the LUTEGA study.

@en

P2093

Dietrich Schweitzer

http://www.w3.org/2001/XMLSchema#string

Gabriele E Lang

http://www.w3.org/2001/XMLSchema#string

Jens Dawczynski

http://www.w3.org/2001/XMLSchema#string

Jürgen Strobel

http://www.w3.org/2001/XMLSchema#string

Martin Hammer

http://www.w3.org/2001/XMLSchema#string

Susanne Jentsch

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress

Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer

The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: a review based on controversial evidence.

Lipoxins and new lipid mediators in the resolution of inflammation

TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD

High concentration of zinc in sub-retinal pigment epithelial deposits

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients.

Light exposure and macular pigment optical density.

P2888

s00417-013-2376-6

P304

2711-2723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00417-013-2376-6

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

251

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236929670

http://www.w3.org/2001/XMLSchema#string

P6179

1029075124

http://www.w3.org/2001/XMLSchema#string

P698

23695657

http://www.w3.org/2001/XMLSchema#string